Evidence Intelligence™
- ImpactScore™
- 65
- Slightly Positive
- EvidenceScore™
- 75
- Strong
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
GLP-1 agonists reduce heart fat thickness in diabetes.
Última actualización 5 de julio de 2026
Key finding
Epicardial adipose tissue thickness significantly decreased in the semaglutide group (P < 0.01).
Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Clinical relevance
This study evaluated Semaglutide and dulaglutide administered weekly to adults with type 2 diabetes and obesity.
Keep in mind
Limitations were not clearly described in the extracted text.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Gianluca I, Alexandra CVF. Weekly administration of GLP-1 receptor agonists semaglutide or dulaglutide reduces epicardial adipose tissue thickness. Journal of the Endocrine Society. 2020;4(4):bvz042. doi:10.1210/jendso/bvz042
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide, Metformin, Semaglutide and BMI, Epicardial adipose tissue thickness, HbA1c.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- BMI
- Epicardial adipose tissue thickness
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
8
Evidence pairs
355
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Metformin Therapies and HbA1c
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Seguir evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Body Mass Index
Seguir evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Epicardial adipose tissue thickness
Dulaglutide → Epicardial adipose tissue thickness
Dulaglutide → Epicardial adipose tissue thickness
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 67
- Slightly Positive
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 75
- Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 80
- Positive
- EvidenceScore™
- 85
- Strong
- ConsistencyScore™
- 83
- consistent
Supporting studies: Based on 7 studies
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 75
- Positive
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ConsistencyScore™
- 75
- consistent
Supporting studies: Based on 4 studies
Add to Evidence TrackerEpicardial adipose tissue thickness
Semaglutide → Epicardial adipose tissue thickness
Semaglutide → Epicardial adipose tissue thickness
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 88
- Very Positive
- EvidenceScore™
- 87
- Strong
- ConsistencyScore™
- 83
- consistent
Supporting studies: Based on 12 studies
Add to Evidence TrackerBuild your personal Evidence Workspace
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Save this study
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, Metformin Therapies and HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceGLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- ImpactScore™
- 88
- Very Positive
- EvidenceScore™
- 87
- Strong
- ConsistencyScore™
- 83
- consistent
Supporting studies: Based on 12 studies
View evidenceMedications
Detailed evidenceMetformin Therapies → HbA1c
Medications
Evidence Intelligence™
- ImpactScore™
- 80
- Positive
- EvidenceScore™
- 85
- Strong
- ConsistencyScore™
- 83
- consistent
Supporting studies: Based on 7 studies
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
12 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
12 studies
outcome_hubMeasures HbA1c as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
7 studies
intervention_hubContributes to Metformin Therapies evidence base.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
12 results
All studies on Metformin and HbA1c
Intervention: MetforminOutcome: HbA1c
7 results
All studies on Semaglutide
Intervention: Semaglutide
12 results
All studies on Metformin
Intervention: Metformin
7 results
All studies measuring HbA1c
Outcome: HbA1c
12 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies improve HbA1c?
Strong Evidence
Metformin Therapies may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.4 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 87.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies affect body mass index?
Strong Evidence
Metformin Therapies appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.